The Economic Utility of an Alzheimer's Disease Blood Biomarker Test in the Evaluation of Cognitively Impaired Patients
In a budget impact model, PrecivityAD2 testing prior to usual care brain amyloid detection methods in patients undergoing evaluation for cognitive impairment provides cost savings and reduces the predicted burden on both patients and payers, while maintaining a high quality of care.
Authors
- Mark Monane (ORCID: https://orcid.org/0000-0003-1550-4415)
- Joel B. Braunstein (ORCID: https://orcid.org/0000-0002-1155-0206)
- William J Canestro
- Randall J. Bateman
- David M. Holtzman
Institutions
- Washington University in St. Louis (US)
- C2N Diagnostics (United States) (US)
- Protein Research Foundation (JP)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_106232
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00